Chemotherapy News and Research

Latest Chemotherapy News and Research

Research reveals balancing act between sugar-coated nanoparticles

A research team at the National Institute of Standards and Technology (NIST) studying sugar-coated nanoparticles for use as a possible cancer therapy has uncovered a delicate balancing act that makes the particles more effective than conventional thinking says they should be. Just like individuals in a crowd respecting other people's personal space, the particles work because they get close together, but not too close.

23 Sep 2009

Drug trial for OSI-906 begins

TGen Clinical Research Services at Scottsdale Healthcare today announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands.

23 Sep 2009

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) demonstrated a significant improvement in overall survival (OS) when added to standard 1st-line chemotherapy for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors.

23 Sep 2009

Breast cancer awareness campaign launched by Samsung Electronics Europe

Samsung Electronics Europe has launched ‘Everybody’s Doing It’, an online campaign and website which is a call to action encouraging women in Europe to check for breast cancer and prevent the disease from spreading. By visiting www.morethantalk.eu women can find an instant community of support, a place to make pledges to raise further awareness and a place to view or forward a short viral movie called ‘Everybody’s Doing It’; containing footage of eight women whose lives have been affected by breast cancer. The viral is intended to reach over 400,000 women - more than the number who are diagnosed with breast cancer in Europe every year.

23 Sep 2009

Hyperthermia with chemotherapy prolongs survival

BSD Medical Corporation (NASDAQ:BSDM) reports that significant and “medical practice changing” clinical study results were the subject of a news briefing at Europe’s largest cancer congress, ECCO15 – ESMO34, which is being held September 20 to 24, 2009, in Berlin, Germany.

23 Sep 2009

Civil action against BioAlliance Pharma gets rejected

BioAlliance Pharma SA (Paris:BIO) announces today that the American District Judge has granted the motion to dismiss of BioAlliance Pharma and one of its executive in response to the civil action filed by Eurofins. Eurofins filed an appeal.

23 Sep 2009

FCI to educate women about fertility preservation

Life-saving cancer treatments such as chemotherapy and radiation can destroy the reproductive potential of both men and women; an added struggle for the 130,000 people in the US diagnosed with cancer each year. The good news is that advances in fertility technologies now give patients the ability to preserve their fertility prior to treatment, an option many oncologists fail to inform their patients.

23 Sep 2009

Obesity can increase cancer incidence in leukemic children

Obesity is an important factor contributing to chemotherapy resistance and increasing relapse rates among children with leukemia, according to recent findings published online first in Cancer Research, a journal of the American Association for Cancer Research.

23 Sep 2009

Oncotype DX Recurrence Score provides consistent results across varied patient populations

Genomic Health, Inc. today, announced results from the first study to compare the distribution of Oncotype DX® Recurrence Score® results between European, Middle Eastern and United States patient populations.

22 Sep 2009

Study reveals effectiveness of targeted heat therapy in addition to chemotherapy

Patients with soft-tissue sarcomas at high risk of spreading were 30% more likely to be alive and cancer free almost three years after starting treatment if their tumours were heated at the time they received chemotherapy, according to new research. The finding bolsters the case for intensifying exploration of the strategy in other types of cancer.

22 Sep 2009

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.

22 Sep 2009

Barbershop singing helps cancer-survivor

For Marguerite Paustenbach, her secret weapon in the fight against breast cancer turned out to be her strong faith and love for barbershop singing. Paustenbach is a member of Village Vocal Chords, a Chicago-based barbershop singing group that’s part of Harmony, Inc., an all women’s barbershop singing organization currently celebrating its 50th anniversary.

22 Sep 2009

Tregs to set the pace of recovery after serious lung injury

After more than 50 experiments in mice, medical scientists at Johns Hopkins have mapped out the basic steps taken by a particular set of white blood cells in setting the pace of recovery after serious lung injury.

22 Sep 2009

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology.

22 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

Nasdaq Stock Market issues noncompliance letter to A.P. Pharma

A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that, on September 15, 2009, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5450(a)(1).

21 Sep 2009

MedWaves reports on its ongoing studies using the AveCure microwave coagulation-ablation system

MedWaves, Inc. announces ongoing investigational studies to determine the effectiveness of its microwave ablation system for treating soft tissue lesions, such as tumors, in liver and lung. The studies using MedWaves' AveCure(TM) microwave coagulation-ablation system, which includes a generator and probe/antenna (FDA 510(k) cleared and CE Mark certified), are showing promising results.

19 Sep 2009

FDA continues review of BSD Medical's HDE for the BSD-2000 Hyperthermia System

BSD Medical Corporation (NASDAQ: BSDM) (www.bsdmedical.com) reported today that the U.S. Food and Drug Administration (FDA) continues its review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System.

19 Sep 2009

EPO and growth factor therapy safe for anemic MDS patients

Myelodysplastic syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells).

18 Sep 2009

Research to identify breast cancer disparities

In an effort to continue to deliver on its vision of a world without breast cancer, Susan G. Komen for the Cure,((R) )San Diego conducted an in-depth, county-wide research and community needs assessment to identify disparities in breast cancer across populations.

18 Sep 2009